Abstract

Chemical reaction prediction, encompassing forward synthesis and retrosynthesis, stands as a fundamental challenge in organic synthesis. A widely adopted computational approach frames synthesis prediction as a sequence-to-sequence translation task, using the commonly used SMILES representation for molecules. The current evaluation of machine learning methods for retrosynthesis assumes perfect training data, overlooking imperfections in reaction equations in popular datasets, such as missing reactants, products, other physical and practical constraints such as temperature and cost, primarily due to a focus on the target molecule. This limitation leads to an incomplete representation of viable synthetic routes, especially when multiple sets of reactants can yield a given desired product. In response to these shortcomings, this study examines the prevailing evaluation methods and introduces comprehensive metrics designed to address imperfections in the dataset. Our novel metrics not only assess absolute accuracy by comparing predicted outputs with ground truth but also introduce a nuanced evaluation approach. We provide scores for partial correctness and compute adjusted accuracy through graph matching, acknowledging the inherent complexities of retrosynthetic pathways. Additionally, we explore the impact of small molecular augmentations while preserving chemical properties and employ similarity matching to enhance the assessment of prediction quality. We introduce SynFormer, a sequence-to-sequence model tailored for SMILES representation. It incorporates architectural enhancements to the original transformer, effectively tackling the challenges of chemical reaction prediction. SynFormer achieves a Top-1 accuracy of 53.2% on the USPTO-50k dataset, matching the performance of widely accepted models like Chemformer, but with greater efficiency by eliminating the need for pre-training.

Abstract

Drug-Drug Interactions (DDI) can trigger unexpected pharmacological consequences, including adverse drug events (ADE). The rise in polypharmacy underscores the importance of understanding how different drug molecules influence each other’s pharmacological activities and necessitates the investigation of potential interactions between newly developed drugs and existing medications. Traditional laboratory methods for DDI detection are time-consuming, making the development of computational prediction methods crucial. This study introduces GraphDDI, a machine learning method utilizing Graph Neural Networks (GNN) to predict DDI accurately. The proposed methodology, trained end-to-end, comprises three stages. (1) Featurization stage: A GNN extracts atomic features from two drugs separately. (2) Interaction stage: an interaction map is calculated between all atom pairs of the drugs. (3) Prediction stage: the model combines the interaction map and drug features to create a unified representation of the drug molecules. Subsequently, the model concatenates these representations and employs a feed-forward neural network to predict the DDI. We demonstrate the efficacy of our proposed model in predicting both the presence of DDI and the specific types of interactions (DDI events). Comparative analysis reveals that our framework surpasses existing models, achieving an F1 score of 0.98 in predicting the existence of drug-drug interactions and 0.90 in categorizing DDI event types. The code is available in our GitHub repository (https://github.com/devalab/GraphDDI).

Abstract

In recent years, the rapid advancement of generative artificial intelligence (GenAI) has revolutionized the landscape of drug design, offering innovative solutions to potentially expedite the discovery of novel therapeutics. GenAI encompasses algorithms and models that autonomously create new data, including text, images, and molecules, often mirroring characteristics of existing datasets. This comprehensive review delves into the realm of GenAI for drug design, emphasizing recent advancements and methodologies that have propelled the field forward. Specifically, we focus on three prominent paradigms: transformers, diffusion models, and reinforcement learning algorithms, which have been exceptionally impactful in the last few years. By synthesizing insights from a myriad of studies and developments, we elucidate the potential of these approaches in accelerating the drug discovery process. Through a detailed analysis, we explore the current state and future directions of GenAI in the context of drug design, highlighting its transformative impact on pharmaceutical research and development.

Abstract

Chemical reaction prediction, encompassing forward synthesis and retrosynthesis, stands as a fundamental challenge in organic synthesis. A widely adopted computational approach frames synthesis prediction as a sequence-to-sequence translation task, using the common SMILES representation for molecules. Current evaluation of machine learning methods for retrosynthesis assume perfect training data, overlooking imperfections in reaction equations in popular datasets, such as missing reactants, products, other physical and practical constraints such as temperature and cost, primarily driven by a focus on the target molecule. This limitation leads to an incomplete representation of viable synthetic routes, especially when multiple sets of reactants can yield a given desired product. In response to these shortcomings, this study examines the prevailing evaluation methods and introduces comprehensive metrics designed to address imperfections in the dataset. Our novel metrics not only assess absolute accuracy by comparing predicted outputs with ground truth but also introduce a nuanced evaluation approach. We provide scores for partial correctness and compute adjusted accuracy through graph matching, acknowledging the inherent complexities of retrosynthetic pathways. Additionally, we explore the impact of small molecular augmentations while preserving chemical properties and employ similarity matching to enhance the assessment of prediction quality. We introduce SynFormer, a sequence-to-sequence model tailored for SMILES representation. It incorporates architectural enhancements to the original transformer, effectively tackling the challenges of chemical reaction prediction. SynFormer achieves a top-1 accuracy of 53.2% on the USPTO-50k dataset, demonstrating an improvement over previous state-of-the-art language models while being more efficient and eliminating the need for pre-training.

Abstract

RNA molecules play a significant role in many biological pathways and have diverse functional roles, which is a result of their structural flexibility to fold into diverse conformations. This structural flexibility makes it challenging to obtain the structures of RNAs experimentally. Deep learning can be used to predict the secondary structures of RNA and other properties such as the backbone torsion angles, to be used as restraints for the computational optimization of the tertiary structures of RNA. TorRNA is a transformer encoder-decoder model, that takes an input RNA sequence and predicts the (pseudo)torsion angles of each nucleotide with a pre-trained RNA-FM model as the encoder. TorRNA is able to achieve a performance boost of 2% − 16% over the previous (pseudo)torsion angle prediction method for RNAs. We also demonstrate that TorRNA can used as a tool for model quality assessment of candidate RNA structures

Abstract

Computing binding affinities is of great importance in drug discovery pipeline and its prediction using advanced machine learning methods still remains a major challenge as the existing datasets and models do not consider the dynamic features of protein-ligand interactions. To this end, we have developed PLAS-20k dataset, an extension of previously developed PLAS-5k, with 97,500 independent simulations on a total of 19,500 different protein-ligand complexes. Our results show good correlation with the available experimental values, performing better than docking scores. This holds true even for a subset of ligands that follows Lipinski’s rule, and for diverse clusters of complex structures, thereby highlighting the importance of PLAS-20k dataset in developing new ML models. Along with this, our dataset is also beneficial in classifying strong and weak binders compared to docking. Further, OnionNet model has been retrained on PLAS-20k dataset and is provided as a baseline for the prediction of binding affinities. We believe that large-scale MD-based datasets along with trajectories will form new synergy, paving the way for accelerating drug discovery.

Abstract

Molecular spectroscopy studies the interaction of molecules with electromagnetic radiation, and interpreting the resultant spectra is invaluable for deducing the molecular structures. However, predicting the molecular structure from spectroscopic data is a strenuous task that requires highly specific domain knowledge. DeepSPInN is a deep reinforcement learning method that predicts the molecular structure when given Infrared and 13C Nuclear magnetic resonance spectra by formulating the molecular structure prediction problem as a Markov decision process (MDP) and employs Monte-Carlo tree search to explore and choose the actions in the formulated MDP. On the QM9 dataset, DeepSPInN is able to predict the correct molecular structure for 91.5% of the input spectra in an average time of 77 seconds for molecules with less than 10 heavy atoms. This study is the first of its kind that uses only infrared and 13C nuclear magnetic resonance spectra for molecular structure prediction without referring to any pre-existing spectral databases or molecular fragment knowledge bases, and is a leap forward in automated molecular spectral analysis.

Abstract

Computational drug discovery is intrinsically interdisciplinary and has to deal with the multifarious factors which are often dependent on the type of disease. Molecular Property Diagnostic Suite (MPDS) is a Galaxy based web portal which was conceived and developed as a disease specific web portal, originally developed for tuberculosis (MPDSTB). As specific computational tools are often required for a given disease, developing a disease specific web portal is highly desirable. This paper emphasises on the development of the customised web portal for COVID-19 infection and is referred to as MPDSCOVID-19. Expectedly, the MPDS suites of programs have modules which are essentially independent of a given disease, whereas some modules are specific to a particular disease. In the MPDSCOVID-19 portal, there are modules which are specific to COVID-19, and these are clubbed in SARS-COV-2 disease library. Further, the new additions and/or significant improvements were made to the disease independent modules, besides the addition of tools from galaxy toolshed. This manuscript provides a latest update on the disease independent modules of MPDS after almost 6 years, as well as provide the contemporary information and tool-shed necessary to engage in the drug discovery research of COVID-19. The disease independent modules include file format converter and descriptor calculation under the data processing module; QSAR, pharmacophore, scaffold analysis, active site analysis, docking, screening, drug repurposing tool, virtual screening, visualisation, sequence alignment, phylogenetic analysis under the data analysis module; and various machine learning packages, algorithms and in-house developed machine learning antiviral prediction model are available. The MPDS suite of programs are expected to bring a paradigm shift in computational drug discovery, especially in the academic community, guided through a transparent and open innovation approach. The MPDSCOVID-19 can be accessed at http://mpds.neist.res.in:8085.

Abstract

With Cardiovascular Diseases on the rise around the world, Electrocardiograms (ECGs) play a crucial role in their diagnosis owing to their non-invasive nature and simplicity. Medical professionals typically use 12-lead ECGs for medical analysis but gathering 12-lead ECG data is an arduous task outside clinical setting. Modern wearables can collect an ECG with fewer leads than the standard 12 leads. However, medical professionals and conventional ECG analysis software find this reduced lead set data challenging to interpret. By using the reduced lead set data to create standard 12-lead ECG data, ECG reconstruction can solve this issue. This paper proposes a novel single-lead to multi-lead ECG reconstruction solution using a modified Attention U-net framework. Using only the lead II of ECG, our model is able to reproduce the other 11 leads of conventional 12-lead ECG with a Pearson correlation, Mean square error and R-squared value of 0.805, 0.0122 and 0.639, respectively. Further, a single combined model is used to reconstruct all 11 leads simultaneously, improving performance and simultaneously reducing the computational resources needed for training compared to current literature in the field. In comparison to previous works, which only reconstruct small ECG segments, our model is trained to reconstruct longer 10-second ECG signals. We demonstrate our model’s ability for real-life utilisation using a cardiovascular disease classification task. A deep learning model was trained for multi-disease classification on actual 12-lead ECG data and was tested on both original and reconstructed 12-lead ECG signals. The classification accuracies for the original and reconstructed signals were comparable, portraying that our reconstruction model can preserve diagnostically relevant artefacts in its reconstructed signals. This work provides a new promising solution in the field of single-lead ECG reconstruction, taking us a step closer to bridging the divide between reduced lead set data and existing 12-lead ECG end users like clinicians and automatic ECG classifiers.

Abstract

In this work, we describe the creation of our machine- learning-based solution for coma prognosis after cardiac arrest using longitudinal EEG and ECG recordings for the ”Predicting Neurological Recovery from Coma After Car- diac Arrest: The George B. Moody PhysioNet Challenge 2023”. Our team, “ComaToast”, had its best submission ranked 28 out of 36 teams selected worldwide, with a chal- lenge score of 0.381 on the official leaderboard for the hid- den test set. We use a combination of age and signal fea- tures from EEG and ECG recordings. Frequency domain features, specifically mean power spectral density from 4 different bands of frequencies (Delta, Theta, Alpha and Beta) and mean Burst Suppression Ratio, were extracted from pre-processed EEG recordings from the first and last available recording for a given patient. Features like mean and standard deviations were extracted along channels for ECG recordings. After imputing missing values, these fea- tures are fed to an XGBoost classifier for the final binary classification of the outcome prediction task. The features are fed to a random forest regressor to predict the CPC outcome for every patient. A solution like ours, which uses a simple model and training technique, may be more viable than deep-learning solutions in general use cases. In our final model, our approach achieved a 5-fold cross- validation score of 0.34 on the public train set.